Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
22 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Nonselective beta blockers tied to portal vein thrombosis in cirrhotic patients

08 Feb 2019

Exposure to nonselective beta blockers contributes to an increased risk of developing portal vein thrombosis in patients with cirrhosis, a study suggests.

The study included 97 outpatients with cirrhosis and no portal vein thrombosis at baseline, of whom 50 percent were on nonselective beta blockers. Researchers performed Doppler ultrasound every 3 or 6 months for a median follow up of 19 months.

Portal vein thrombosis occurred in 11 patients (10.2 percent) during follow-up. Occlusion of the portal vein was complete in two patients and partial in nine. Most of the patients were male (54.6 percent male) and had Child-Pugh A cirrhosis (81.8 percent).

Significant risk factors for incident portal vein thrombosis included nonselective beta blockade (hazard ratio [HR], 10.56; 95 percent CI, 1.35–82.73; p=0.025) and a history of medium- or large‐sized oesophageal varices at baseline (HR, 5.67; 1.49–21.63; p=0.011).

Conversely, heart rate and portal blood flow velocity at baseline showed no association with the risk of portal vein thrombosis, although the two variables were significantly improved by nonselective beta blockers.

Researchers pointed out the need for further investigation to characterize the mechanisms that explain portal vein thrombosis development in cirrhotic patients on nonselective beta blockers in order to optimize targeting of nonselective beta blockers in this population.

Nonselective beta blockers is the gold standard in the prevention of first and recurrent variceal bleeding. The goal is to lower portal hypertension through β1 receptor blockade, which reduces cardiac output, and β2 receptor blockade, which causes splanchnic vasoconstriction. It has been postulated that β1 and β2 blockade may lead to portal vein thrombosis development by reducing portal vein inflow and portal flow velocity. [World J Gastroenterol 2014;20:11463‐11466; Expert Opin Pharmacother 2003;4:625‐637]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
22 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.